The positive Part 2 results materially improve the risk/reward for obefazimod's NDA submission in Q4 2026. Traders should monitor for FDA acceptance and potential advisory committee meeting.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $133.26entry
- T+1 · 5mo ago −0.53%α −0.39% · $132.56
- T+5 · 4mo ago +8.05%α +7.45% · $143.99
- T+20 · 4mo ago −3.95%α −2.92% · $128.00
- T+60 · 8w ago −29.36%α −32.18% · $94.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abivax reported positive topline results from ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission in induction non-responders and 45.5% recapture of remission in relapsers. The expanded safety database (1,704 patient-years) showed malignancy rates consistent with UC background rates. The company remains on track for NDA submission in Q4 2026.
Key Facts
- 37.2% of induction non-responders achieved clinical remission at Week 44 on 50 mg obefazimod
- 45.5% of patients who relapsed on 25 mg and escalated to 50 mg recaptured clinical remission
- Exposure-adjusted malignancy rates (excluding NMSC) were 0.35 per 100 PY in all-active combined, within UC background range of 0.30–0.70
- NDA submission for obefazimod in UC remains on track for Q4 2026
- Integrated safety database includes 1,704 patient-years of exposure across Phase 2 and Phase 3 programs
Financial Impact
Positive Phase 3 maintenance data strengthens NDA package and de-risks approval path for obefazimod, a potential blockbuster UC therapy. Stock price reaction likely significant given prior safety concerns are addressed with expanded dataset.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) despite expanded safety data
- Competition from existing and emerging UC therapies (JAK inhibitors, IL-23 blockers) could limit commercial uptake
- Long-term safety monitoring continues; any new signal could derail approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319283 |
Track record
10 reports on ABVX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $87.58 +5.01% settles Nov 24
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $87.58 +1.14% ▼ −0.99% +1.71% vs SPY
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $87.58 −32.63% ▼ −6.58% −7.79% vs SPY
- Jul 2, 202619w ago 6-K Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
- Jul 2, 202619w ago 424B5 Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
- Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $87.58 +33.93% ▼ −7.25% −6.99% vs SPY
- Jun 29, 202620w ago 6-K Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
- Jun 29, 202620w ago Press Release Bullish 7/10 Viewing Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
- May 22, 202625w ago Press Release Neutral 5/10 Entry $126.41 to $129.69 Now $87.58 −30.72% ▲ +2.59% +1.51% vs SPY
- Mar 23, 202634w ago Press Release Mixed 6/10 Entry $110.17 to $111.35 Now $87.58 −20.50% ▲ +1.07% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers